These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 6002050)

  • 21. [Therapy monitoring of regional chemotherapy by magnetic resonance spectroscopy].
    Semmler W; Bachert-Baumann P; Schlag P; Gückel F; Lorenz WJ; Van Kaick G
    Z Gastroenterol Verh; 1989 Jul; 24():202-3. PubMed ID: 2474953
    [No Abstract]   [Full Text] [Related]  

  • 22. [Extremity perfusion in malignant melanoma].
    Hohenberger W; Meyer T; Göhl J
    Chirurg; 1994 Mar; 65(3):175-85. PubMed ID: 8194401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Regional perfusion treatment in primary malignant melanomas of the extremities. (Microstage IV/V according to Clark and tumor thickness over 1.5 mm)].
    Schraffordt Koops H; Oldhoff J
    Hautarzt; 1982 Sep; 33(9):506-10. PubMed ID: 7174325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
    Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
    Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modern therapeutic approach to malignant melanoma.
    Poole WL
    South Med J; 1971 Dec; 64(12):1449-51. PubMed ID: 5131324
    [No Abstract]   [Full Text] [Related]  

  • 26. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
    Kettelhack C; Hohenberger P; Schlag PM
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Unilateral leukopathia unguis toxica and diffuse hair loss after cytostatic perfusion of an extremity].
    Zaun H; Omlor G
    Hautarzt; 1992 Apr; 43(4):215-6. PubMed ID: 1534553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
    Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
    J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Value of regional lymph node excision for prognosis of advanced malignant melanoma treated by perfusion of the extremity].
    Huber R; Krüger I; Stützer H
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():118-21. PubMed ID: 9101808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimizing regional therapy for melanoma.
    Beasley GM; Tyler DS
    Ann Surg Oncol; 2009 May; 16(5):1095-7. PubMed ID: 19189189
    [No Abstract]   [Full Text] [Related]  

  • 32. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan.
    Vaglini M; Santinami M; Manzi R; Inglese MG; Santoro N; Persiani L; Belli F
    Melanoma Res; 1994 Mar; 4 Suppl 1():35-8. PubMed ID: 8038594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective regional perfusion of the bilateral external carotid arteries with pegylated liposomal doxorubicin and melphalan to treat metastatic malignant melanoma of the scalp.
    Göppner D; Quist SR; Franke I; Ulrich J; Drecoll U; Bürger T; Gollnick HP; Bonnekoh B
    Clin Exp Dermatol; 2011 Apr; 36(3):270-2. PubMed ID: 20659118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolated hepatic perfusion for liver metastases of malignant melanoma.
    Rizell M; Mattson J; Cahlin C; Hafström L; Lindner P; Olausson M
    Melanoma Res; 2008 Apr; 18(2):120-6. PubMed ID: 18337648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perfusion of melanoma. 105 isolated perfusions in 92 patients.
    Golomb FM
    Oncology; 1972; 26(2):197-205. PubMed ID: 4626136
    [No Abstract]   [Full Text] [Related]  

  • 37. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs.
    Vrouenraets BC; Eggermont AM; Klaase JM; Van Geel BN; Van Dongen JA; Kroon BB
    Eur J Surg Oncol; 1994 Dec; 20(6):681-5. PubMed ID: 7995421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolated limb perfusion.
    Moffat EP
    Nurs Times; 1969 Jan; 65(5):138-40. PubMed ID: 5763585
    [No Abstract]   [Full Text] [Related]  

  • 40. [Missed opportunities in malignant melanomas?].
    Kuijjer PJ
    Ned Tijdschr Geneeskd; 1967 Jul; 111(26):1149-52. PubMed ID: 6046661
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.